당뇨병성 망막증 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global diabetic retinopathy market size is expected to reach USD 20.19 Billion in 2034 from USD 6.22 Billion in 2025, growing at a CAGR of 13.97% during 2026-2034.The global diabetic retinopathy market is expanding significantly due to the rising global burden of diabetes. As the number of diabetic patients increases, the risk of vision-related complications is also growing, driving demand for effective diagnostic and treatment solutions. Early screening programs and improved imaging technologies have enhanced detection rates, supporting market growth.

Major drivers include advancements in anti-VEGF therapies, laser treatments, and surgical interventions. Increasing awareness about regular eye examinations and government initiatives promoting diabetes management are further strengthening market expansion. The integration of artificial intelligence in retinal imaging is also improving diagnostic accuracy and efficiency.

Looking forward, the market is expected to benefit from continued innovation in biologic therapies and long-acting treatment options. Teleophthalmology services and digital health platforms may expand access to eye care, particularly in rural areas. As healthcare systems focus on preventing diabetes-related complications, the demand for diabetic retinopathy treatments is projected to grow steadily in the coming years.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Proliferative Diabetic Retinopathy
• Diabetic Macular Edema (DME)

By Treatment Type

• Anti VEGF Drug
• Steroid Implants
• Laser Surgeries
• Vitrectomy

COMPANIES PROFILED

• Regeneron Pharmaceuticals, Roche, Bayer, Novartis, AbbVie, Alimera Sciences, Genentech, Apellis Pharmaceuticals, Oxurion, Kodiak Sciences, EyePoint Pharmaceuticals, Santen Pharmaceutical, Ocular Therapeutix, Clearside Biomedical, REGENXBIO, Adverum Biotechnologies, 4D Molecular Therapeutics, Opthea, Janssen, Eli Lilly

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIABETIC RETINOPATHY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Proliferative Diabetic Retinopathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Diabetic Macular Edema (DME) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIABETIC RETINOPATHY MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Anti VEGF Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Steroid Implants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Laser Surgeries Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Vitrectomy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIABETIC RETINOPATHY MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By Treatment Type
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By Treatment Type
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Spain
  • 6.3.8 Russia
  • 6.3.9 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By Treatment Type
  • 6.4.3 China
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 India
  • 6.4.7 Australia
  • 6.4.8 South East Asia
  • 6.4.9 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By Treatment Type
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By Treatment Type
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL DIABETIC RETINOPATHY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Regeneron Pharmaceuticals
  • 8.2.2 Roche
  • 8.2.3 Bayer
  • 8.2.4 Novartis
  • 8.2.5 AbbVie
  • 8.2.6 Alimera Sciences
  • 8.2.7 Genentech
  • 8.2.8 Apellis Pharmaceuticals
  • 8.2.9 Oxurion
  • 8.2.10 Kodiak Sciences
  • 8.2.11 EyePoint Pharmaceuticals
  • 8.2.12 Santen Pharmaceutical
  • 8.2.13 Ocular Therapeutix
  • 8.2.14 Clearside Biomedical
  • 8.2.15 REGENXBIO
  • 8.2.16 Adverum Biotechnologies
  • 8.2.17 4D Molecular Therapeutics
  • 8.2.18 Opthea
  • 8.2.19 Janssen
  • 8.2.20 Eli Lilly